Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

POSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION

15 Sep 2020 07:00

RNS Number : 9628Y
Amryt Pharma PLC
15 September 2020
 

AMRYT PHARMA PLC

("Amryt" or the "Company")

 

AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103

 

DUBLIN, Ireland, and Boston MA, September 15 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce that the European Medicines Agency ("EMA") Committee for Orphan Medicinal Products ("COMP") has adopted a positive opinion for orphan designation for the use of AP103 in Epidermolysis Bullosa ("EB"). AP103 is based on Amryt's gene-therapy platform technology and offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa ("DEB"), a subset of EB.

 

Orphan drug designation in the EU is granted by the European Commission within 30 days of a positive opinion being issued by the EMA COMP. This designation provides certain regulatory and financial incentives including but not limited to product market exclusivity for ten years in the EU following regulatory approval. Orphan designation is available to companies developing products intended to treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union, and where the treatment provides a significant benefit to those affected by the condition or no satisfactory treatment is available. Amryt plans to submit an orphan drug designation request for AP103 to the US Food and Drug Administration ("FDA") in the near future.

 

Dr Joe Wiley, CEO of Amryt Pharma, commented: "Receiving this positive opinion from the EMA for our gene-therapy candidate, AP103, is a significant development for patients suffering from Epidermolysis Bullosa and provides additional momentum to our development pipeline. Unlike other gene therapies that rely on viral vectors, AP103 is based on a novel polymer-based topical delivery platform, which we believe offers potential advantages in the gene-therapy field and has potential to be used in other genetic skin conditions. Alongside our recent positive top line readout from our Phase 3 EASE trial in FILSUVEZ®, today's news further illustrates the exciting clinical opportunities in Amryt's portfolio. These milestones relating to our efforts in Epidermolysis Bullosa are significant for all Amryt stakeholders as we build a global Epidermolysis Bullosa franchise and become a leader in rare and orphan diseases."

 

About AP103

AP103 is currently in preclinical development for the treatment of patients with DEB, a subset of EB. AP103 is the first gene therapy product candidate based on our novel polymer-based topical gene-therapy delivery platform, which also has potential use for the treatment of other rare genetic diseases. Amryt intends to initiate clinical development of AP103 in the first half of 2022.

 

About Epidermolysis Bullosa

EB is a rare, chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate and affects infants, children and adults. The global incidence of EB is estimated to be approximately 1 in 20,000, which implies that there are as many as 30,000 affected individuals in the US and over 500,000 worldwide. There are currently no approved treatments. The global market opportunity for EB is estimated by the Company to be in excess of $1.0 billion.

 

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

 

 

LifeSci Advisors, LLC

+1 (212) 915 2564

Tim McCarthy

 

Consilium Strategic Communications

+44 (0) 20 3709 5700

Amber Fennell, Matthew Neal, Ashley Tapp

 

 

About Amryt

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryt's commercial business comprises two orphan disease products.

Juxtapid®/ Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the trade name Juxtapid®) and in the EU (under the trade name Lojuxta®). HoFH is a rare genetic disorder which impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature cardiovascular disease.

Myalept® / Myalepta® (metreleptin) is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. Metreleptin is also approved for lipodystrophy in Japan. Generalised and partial lipodystrophy are rare disorders characterised by loss or lack of adipose tissue resulting in the deficiency of the hormone leptin, produced by fat cells and are associated with severe metabolic abnormalities including severe insulin resistance, diabetes, hypertriglyceridemia and fatty liver disease.

Amryt's lead development candidate, FILSUVEZ® is a potential treatment for the cutaneous manifestations of EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. In September 2020, Amryt reported positive top line results from its pivotal global phase 3 trial of FILSUVEZ® in EB. The primary endpoint of the trial was met (p-value = 0.013). FILSUVEZ® has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration. The global market opportunity for EB is estimated by the Company to be in excess of $1.0 billion.

In March 2018, Amryt in-licenced a preclinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. 

For more information on Amryt, including products, please visit www.amrytpharma.com.

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014.

 

The person making this notification on behalf of Amryt is Rory Nealon, CFO/COO and Company Secretary.

 

Financial Advisors

Shore Capital (Edward Mansfield, Daniel Bush, John More) are NOMAD and Joint Broker to Amryt in the UK. Stifel (Ben Maddison) are Joint Broker to the company in the UK. Davy (John Frain, Daragh O'Reilly) act as Joint Broker to the company.

Forward-Looking Statements

Statements in this announcement with respect to Amryt's business, strategies, timing for completion of and announcing results from the EASE trial, the potential impact of closing enrollment in the EASE trial, as well as other statements that are not historical facts are forward-looking statements involving risks and uncertainties which could cause the actual results to differ materially from such statements. Statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company's current beliefs and assumptions and are based on information currently available to management.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBZLLFBKLZBBE
Date   Source Headline
27th Nov 20142:32 pmRNSHolding(s) in Company
15th Sep 201412:56 pmRNSResult of AGM
21st Aug 20147:00 amRNSPosting of Annual Report 2014 and Notice of AGM
20th Aug 20147:00 amRNSDirector/PDMR Shareholding
18th Aug 20147:00 amRNSFinal Results for the year ended 31 March 2014
14th Aug 20147:00 amRNSImprovement of Deep Kinsale Option
8th Jul 20143:26 pmRNSHolding(s) in Company
7th Jul 20147:00 amRNSOperational Update
11th Jun 20147:00 amRNSDirector/PDMR Shareholding
22nd May 20147:00 amRNSCorporate Update and Revised Investor Presentation
12th May 20147:00 amRNSAppointment of Chief Financial Officer
6th May 20147:01 amRNSFoum Assaka Well Update
30th Apr 20147:00 amRNSCompletion of Foum Assaka Licence Farm-out
17th Mar 20147:00 amRNSSpudding of Foum Assaka Well
24th Feb 20147:00 amRNSUpdate on Foum Assaka well
12th Feb 20147:00 amRNSFoum Assaka Extension Period Agreement
6th Feb 20147:00 amRNSLicensing Options extended
17th Jan 20147:00 amRNSDirectorate Change
3rd Jan 20147:00 amRNSRig Share Agreement on Foum Assaka Block
19th Dec 201311:59 amRNSHolding(s) in Company
19th Dec 20137:00 amRNSInterim Results
18th Dec 20137:00 amRNSFarmout Agreement signed in Foum Assaka Block
16th Dec 201311:16 amRNSResult of General Meeting
5th Dec 20137:00 amRNSChange of Joint Broker
27th Nov 20137:00 amRNSPlacing of New Shares to Raise £10 Million
18th Nov 20137:00 amRNSKosmos Provides Update on Foum Assaka Permit
14th Nov 20137:00 amRNSFoum Assaka Farm-Out Update
12th Nov 20137:00 amRNSResources Estimates Completed Onshore Morocco
15th Oct 201312:06 pmRNSKosmos Agrees Farm-out of Foum Assaka Permit
7th Oct 20137:00 amRNSApplication of the Takeover Code
24th Sep 20131:05 pmRNSResult of AGM
29th Aug 20137:00 amRNSPosting of Annual Report 2013 and Notice of AGM
19th Aug 20137:00 amRNSFinal Results
4th Jun 20137:00 amRNSCorporate Update and Revised Investor Presentation
29th May 20137:00 amRNSFASTNET TO FARM IN TO TENDRARA LAKBIR
22nd May 20137:00 amRNSDeep Kinsale
3rd May 20137:00 amRNSAward of licensing option in the North Celtic Sea
10th Apr 20137:00 amRNSIncrease in Resources Estimates in Shanagarry
25th Mar 20137:00 amRNSData room opening and grant of options
19th Mar 20137:00 amRNSFastnet Oil & Gas 3D Seismic and Farm-Out
21st Feb 20137:00 amRNSDeep Kinsale Prospect Farm-In
18th Feb 20137:00 amRNS3D Seismic Contract Award
18th Dec 20127:00 amRNSInterim Results
13th Dec 20124:51 pmRNSHolding(s) in Company
13th Dec 201210:36 amRNSHolding(s) in Company
12th Dec 20127:00 amRNSAdmission of new shares and total voting rights
12th Dec 20127:00 amRNSEnterprise Securities Market Notice
10th Dec 20122:20 pmRNSResult of General Meeting
23rd Nov 20123:56 pmRNSHolding(s) in Company
23rd Nov 201212:00 pmRNSDespatch of Shareholder Circular and Notice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.